In December 2020, for the first time in France, a woman named Mauricette was able to benefit from a first vaccine injection using the RNA-Messenger technique, a few months after the start of clinical trials. A feat of speed, but above all a medical revolution to come according to scientists. As a reminder, the classic vaccine consists of injecting inactivated virus into the body to trigger antibodies and an immune reaction. The RNA-Messenger technique consists of injecting a well-chosen piece of the virus’s DNA to give our cells the recipe for fighting the disease. And this would be available for many other pathologies. Moreover, Steve Pascolo, researcher at the Zurich hospital (Switzerland) and founder of Curevac, explains to us that “theoretically, there is an RNA-Messenger solution for each disease, in the form of a vaccine, against cancers, viruses, bacteria, or in non-vaccine and therapeutic form “. Research is continuing on the RNA-Messenger technique at this very moment. They began twenty years ago and several laboratories are in the line, including Pfizer associated with BioNTech or the Americans of Moderna whose boss is French.
– .
